問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung (在職)

Division of Nephrology

Taipei Veterans General Hospital (在職)

Division of Nephrology

Division of Neurology

Kaohsiung Veterans General Hosptial

Division of Orthopedics

Chi Mei Medical Center

Division of Infectious Disease

更新時間：2023-09-19

陳俊宇Chen, Chun-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) -16 years -1 個月

  • shilewu@gmail.com

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳俊宇

List

24Cases

2020-03-31 - 2022-11-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2022-08-01 - 2029-06-04

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-05-02 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-02-01 - 2029-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-04-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2025-01-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-11-01 - 2026-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-09-01 - 2024-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting10Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2019-06-15 - 2023-09-14

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Cemdisiran (ALN-CC5)

Participate Sites
6Sites

Recruiting6Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB